Subject(s)
Enophthalmos , Pain , Age of Onset , Humans , Orbit , Pressure , Tomography, X-Ray ComputedABSTRACT
Appendiceal mucoceles are rare cystic lesions with an incidence of 0.3-0.7% of all appendectomies. They are divided into four subgroups according to their histology. Even though the symptoms may vary - depending on the level of complication - from right lower quadrant pain, signs of intussusception, gastrointestinal bleeding to an acute abdomen with sepsis, most mucoceles are asymptomatic and found incidentally. We present the case of a 70-year-old patient with an incidentally found appendiceal mucocele. He was seen at the hospital for backache. The CT scan showed a vertebral fracture and a 7-cm appendiceal mass. A preoperative colonoscopy displayed several synchronous adenomas in the transverse and left colon with high-grade dysplasia. In order to lower the cancer risk of this patient, we performed a subtotal colectomy. The appendiceal mass showed no histopathological evidence of malignancy and no sign of perforation. The follow-up was therefore limited to 2 months. In this case, appendectomy would have been sufficient to treat the mucocele alone. The synchronous high-grade dysplastic adenomas were detected in the preoperative colonoscopy and determined the therapeutic approach. Generally, in the presence of positive lymph nodes, a right colectomy is the treatment of choice. In the histological presence of mucinous peritoneal carcinomatosis, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is indicated. In conclusion, mucoceles of the appendix are detected with high sensitivity by CT scan. If there is no evidence of synchronous tumor preoperatively and no peritoneal spillage, invasion or positive sentinel lymph nodes during surgery, a mucocele is adequately treated by appendectomy.
ABSTRACT
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are common primary hepatic malignancies. Their immunohistological differentiation using specific markers is pivotal for treatment and prognosis. We found alphavbeta6 integrin strongly upregulated in biliary fibrosis, but its expression in primary and secondary liver tumours is unknown. Here, we aimed to evaluate the diagnostic applicability of alphavbeta6 integrin in differentiating primary liver cancers. METHODS: Expression of alphavbeta6 integrin was evaluated in liver tissues from patients with CC, HCC, fibrolamellar HCC, combined CC/HCC, hepatic metastases of colorectal and pancreatic carcinomas, primary sclerosing cholangitis (PSC), and in human primary and tumour-derived liver cell lines by immunohisto- and cytochemistry, and by TaqMan PCR. Diagnostic performance of the beta6 subunit was compared with CK7, CK20, and HepPar 1. RESULTS: In CC cells beta6 mRNA levels were induced 125-fold compared to primary cholangiocytes, while it was completely absent in hepatoma cells. In human tissues, beta6 transcripts were more than 100-fold upregulated in CC compared to normal liver. By immunohistochemistry, 88% of CC, 50% of PSC, 13% of colorectal carcinoma metastases, and 80% of pancreatic carcinoma metastases presented alphavbeta6, whereas all HCC, combined CC/HCC and fibrolamellar HCC stained negative. Specificity of beta6 immunohistochemistry for CC (100%) surpassed all other tested markers and sensitivity was equal to CK7 (86% vs. 90%). CONCLUSION: The alphavbeta6 integrin is strongly expressed in human CC but not in HCC and therefore can be considered as a specific immunohistochemical marker in the differential diagnosis of primary liver tumours.
Subject(s)
Antigens, Neoplasm/metabolism , Bile Duct Neoplasms/diagnosis , Bile Duct Neoplasms/metabolism , Bile Ducts, Intrahepatic , Biomarkers, Tumor/metabolism , Cholangiocarcinoma/diagnosis , Cholangiocarcinoma/metabolism , Integrins/metabolism , Aged , Aged, 80 and over , Bile Duct Neoplasms/pathology , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cholangiocarcinoma/pathology , Cholangitis, Sclerosing/diagnosis , Cholangitis, Sclerosing/metabolism , Cholangitis, Sclerosing/pathology , Diagnosis, Differential , Female , Humans , Keratin-20/metabolism , Keratin-7/metabolism , Liver Neoplasms/diagnosis , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Male , Middle Aged , Sensitivity and SpecificityABSTRACT
N-myc downstream-regulated gene-1 (NDRG1) is a recently described hypoxia-inducible protein that is upregulated in various human cancers. Pancreatic ductal adenocarcinoma, called pancreatic cancer, is a highly aggressive cancer that is characterised by its avascular structure, which results in a severe hypoxic environment. In this study, we investigated whether NDRG1 is upregulated in these tumours, thus providing a novel marker for malignant cells in the pancreas. By immunohistochemistry, we observed that NDRG1 was highly expressed in well-differentiated cells of pancreatic cancer, whereas the poorly differentiated tumour cells were negative. In addition, hyperplastic islets and ducts of nonquiescent pancreatic tissue were positive. To further explore its selective expression in tumours, two well-established pancreatic cancer cell lines of unequal differentiation status were exposed to 2% oxygen. NDRG1 mRNA and protein were upregulated by hypoxia in the moderately differentiated Capan-1 cells; however, its levels remained unchanged in the poorly differentiated Panc-1 cell line. Taken together, our data suggest that NDRG1 will not serve as a reliable marker of tumour cells in the pancreas, but may serve as a marker of differentiation. Furthermore, we present the novel finding that cellular differentiation may be an important factor that determines the hypoxia-induced regulation of NDRG1.
Subject(s)
Carcinoma, Pancreatic Ductal/genetics , Cell Cycle Proteins/genetics , Cell Differentiation , Cell Hypoxia , Gene Expression Regulation, Neoplastic/genetics , Intracellular Signaling Peptides and Proteins/genetics , Pancreatic Neoplasms/genetics , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Pancreatic Ductal/metabolism , Carcinoma, Pancreatic Ductal/pathology , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins/metabolism , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tumor Cells, Cultured , Up-Regulation/geneticsSubject(s)
Adjustment Disorders/diagnosis , Colitis, Collagenous/diagnosis , Diarrhea/etiology , Adjustment Disorders/psychology , Biopsy , Chronic Disease , Colitis, Collagenous/pathology , Diagnosis, Differential , Endoscopy, Gastrointestinal , Female , Humans , Intestinal Mucosa/pathology , Middle Aged , Recurrence , Sick RoleABSTRACT
Paratesticular sarcomas are rare. We discuss this entity with the aid of a case report and the existing literature. The therapy of these tumors includes resection and possible adjuvant radiotherapy. Rhabdomyosarcomas are an exception, because they also show a good response to chemotherapy.
Subject(s)
Leiomyosarcoma/surgery , Testicular Neoplasms/surgery , Diagnosis, Differential , Humans , Leiomyosarcoma/diagnosis , Leiomyosarcoma/pathology , Male , Middle Aged , Orchiectomy , Testicular Neoplasms/diagnosis , Testicular Neoplasms/pathology , Testis/pathologyABSTRACT
1. Thoracic outlet syndrome is a general term referring to compression neuropathies of the brachial plexus and subclavian vessels. 2. The symptoms result from compression of the brachial plexus or the subclavian vessels; the most common are pain and paresthesia but these may be accompanied by complaints of muscle weakness and easy fatigability of the extremity. 3. First rib resection has been proven valuable; however, because of the possibility of severe and irreversible complications, surgery should be used as a last resort.
Subject(s)
Ribs/surgery , Thoracic Outlet Syndrome/surgery , Thoracic Surgery/nursing , Humans , Surgical Instruments , Thoracic Outlet Syndrome/nursingABSTRACT
The problem of real distress from the discomfort of collapsing scoliosis is predictable in Duchenne muscular dystrophy (DMD). Once the lumbar curve has exceeded 35 degrees, further progression is inevitable. A vital capacity, then, of 35% or more permits consideration of spinal surgery. Using these indications, 24 patients with DMD had long Harrington instrumentations and spinal fusions from S1 up to the upper thoracic spine (T4, 5, or 6). After two weeks recumbent, they were mobilized wearing a light spinal support in their wheelchairs. The complications encountered are described in detail. One patient died two years after his operation from dystrophic cardiomyopathy. With a follow-up period of four months to 42 months, the rest of these patients are well and sitting with comfort. The authors think that this experience indicates that prophylactic spinal fusion deserves consideration in the care planned for these patients.